摘要
目的:人肾上腺髓质素2(AMD2)在甲亢性心脏病患者131I治疗前后血浆中的变化。方法:放射免疫分析及酶联免疫法测定30例体检健康者和25例甲亢性心脏病患者131I治疗前后的血浆AMD2和FT3、FT4水平。结果:与正常健康人比较,甲亢患者血浆AMD2明显低于正常人组(P<0.01),经131I治疗3个月后与正常人组比较无显著性差异,且AMD2与FT3、FT4水平呈明显负相关(r=-0.7099,P<0.01,r=-0.8754,P<0.001)。结论:甲亢性心脏病患者血浆AMD2浓度明显降低,引起降低的原因可能与FT3、FT4升高相关,血浆AMD2可以作为甲亢性心脏病的一个观察指标。
Objective To study the clinical significance of determination the changes of plasma levels of adrenomedullin2（AMD2） in patients with hyperthyroid heart disease.Methods Plasma AMD2（with ELISA）,FT3 and FT4（with RIA） levels were determined in 25 patients with hyperthyroid heart disease and 30 normal healthy controls.Results Compared with the control group,the plasma AMD2 level in patients with hyperthyroid heart disease was decreased（P0.01） apparently,and AMD2 showed significantly negatively correlated to FT3 and FT4（r=-0.7099,P0.01,r=-0.8754,P0.001）.Conclusion Plasma adrenomedullin2 concentration was prominently decreased in patients with hyperthyroid heart disease,the cause of decrease maybe closely related to the increase of FT3,FT4.Plasma AMD2 could be used as an auxiliary index in the diagnosis of hyperthyroid heart disease.
出处
《放射免疫学杂志》
CAS
2012年第6期623-625,共3页
Journal of Radioimmanology
基金
湖北省教育厅科学技术研究项目(项目编号:B20102116)
